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Body sodium-blood volume state, aldosterone, and cardiovascular
responsiveness after calcium entry blockade with nifedipine. Exchange-
able sodium, blood volume, plasma norepinephrine (NE), epinephrine,
renin and aldosterone levels, and pressor responses to infused NE or
angiotensin II (All) were assessed in ten patients with essential hyper-
tension on placebo, following 6 to 8 weeks of calcium-antagonist
nifedipine (NIF), 3 x 10 to 20 mg/day,and after 6 to 8 weeks on NIF
combined with the diuretic chlorthalidone (CHLOR), 25 to 50 mg/day.
Pressor effects of infused calcium also were evaluated on placebo and
NIF. Supine blood pressure was decreased from 151/97 5/2 (5EM) to
132/88 6/2 mm Hg after NIF alone (P < 0.05) and to 124/83 7/3 mm
Hg after NIF + CHLOR (P < 0.01). Body wt was increased from 72.7
to 73.9 kg on NIF alone (P < 0.05), but decreased to 72.1 (P < 0.05
compared with placebo) after adding CHLOR. Exchangeable sodium
also rose from 2642 237 to 3360 266 mmoles on NIF (+ 27%; P <
0.01) and returned to control values (2638 248 mmoles) after addition
of CHLOR. Plasma volume was only slightly modified on NIF (from
2621 193 to 2751 l60 ml; + 5%), but was reduced to 2232 231 ml
on NIF + CHLOR (P < 0.05). Responses of circulating aldosterone to
All were similarly diminished (P < 0.01) during both conditions. Heart
rate, supine and upright plasma renin, aldosterone and catecholamine
levels, and pressor responses to NE, All, or calcium were not consis-
tently changed. These findings indicate that in the established phase of
treatment, NIF may exert its antihypertensive effect without necessar-
ily altering cardiovascular responsiveness to NE and All. However,
calcium antagonism with NIF blunts aldosterone responsiveness to All
and this alteration persists following addition of a diuretic. Mild sodium
retention may develop on NIF, and much of this sodium seems to be
distributed to an extracellular compartment. The addition of a thiazide
diuretic may restore body sodium, slightly reduce blood volume, and
complement the blood pressure-lowering effect of calcium antagonist
therapy with NIF in essential hypertension. Furthermore, the pressor
responses to acute mild hypercalcemia are not mediated by an en-
hanced influx of calcium through the slow transmembranous channels.
Sodium corporel-volume sanguin, aldosterone, et reponse cardiovas-
culaire apres blocage de l'entrée du calcium par Ia nifédipine. Le sodium
échangeable, le volume sanguin, Ia noradrénaline (NE), l'adrénaline, Ia
rénine, et l'aldostérone plasmatiques, et les réponses pressives a une
perfusion de NE ou d'angiotensine II (All) ont été mesurés chez dix
malades atteints d'hypertension essentielle sous placebo, après 6 a 8
semaines de nifédipine (NIF) un antagoniste du calcium, 3 x 10 a 20
mg/jour, Ct aprês 6 a 8 semaines de NIF en association avec de Ia
chlorthalidone (CHLOR) un diuretique, 25 6 50 mg/jour. Les effets
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presseurs d'une perfusion de calcium ont également été évalués sous
placebo et sous NIF. La pression sanguine en décubitus était diminuée
de 151/97 5/2 (5EM) a 132/88 6/2 mm Hg aprés NIF seul (P < 0.05)
et a 124/83 7/3 mm Hg après NIF + CHLOR (P < 0.01). Le poids
corporel a augmenté de 72.7 a 73.9 kg avec NIF seul (P < 0.05), mais
a diminud 6 72.1 (P < 0.05 par rapport au placebo) après addition de
CHLOR. Le sodium échangeable a également augmenté de 2.642 237
a 3.360 266 mmoles avec NIF (+ 27%; P < 0.01) et est revenu aux
valeurs contrôles (2.638 248 mmoles) aprés addition de CHLOR. Le
volume plasmatique n'était que modiflé légerement avec NIF (de 2.621
193 a 2.751 160 ml; + 5%), mais était réduit a 2,232 231 ml avec
NIF et CHLOR (P < 0.05). Les réponses de l'aldostdrone circulante 6
All étaient également diminuées (P < 0.01) dans chaque condition. Le
rythme cardiaque, Ia refine plasmatique couchCe et debout, les niveaux
d'aldostCrone et de catCcholamines, et les rCponses pressives a NE, All
ou calcium n'Ctaient pas changes de facon consistante. Ces rdsultats
indiquent qu'a Ia phase Ctablie du traitement, NIF pourrait exercer son
effet hypotenseur sans altérer nécessairement les rCponses
cardiovasculaires a NE et All. Cependant l'antagonisme calcique avec
NE diminue Ia rCponse de l'aldostérone a All, et cette alteration
persiste après adjonction d'un diurCtique. Une retention sodée modérée
peut apparaltre sous NIF, et Ia plupart de cc sodium semble Ctre
distribué dans Ic compartiment extra-cellulaire. L'adjonction d'un
diurétique thiazidique pourrait restaurer le sodium corporel, diminuer
lCgerement Ic volume sanguin, et completer l'effet d'abaissement de Ia
pression sanguine du traitement par l'antagoniste calcique avec NIF
dans l'hypertension essentielle. Dc plus, les rCponses pressives a une
hypercalcemie aiguë modérée ne sont pas mCdiées par un influx
augmentd de calcium a travers les canaux transmembranaires lents.
The potential of transmembranous calcium entry blockers,
given either as single dose or at short term, to reduce blood
pressure (BP) in essential and certain other forms of hyperten-
sion is now well established [1—4]. A decrease in basal vascular
muscle tone, resulting from reduced intracellular free calcium,
is probably of prime importance for this action. Moreover,
calcium antagonists may modulate BP through additional regu-
latory factors, such as the sympathetic and renin-angiotensin
systems [1,5,61, the vascular reactivity to norepinephnne (NE)
or angiotensin II (All) [7—10], and perhaps also the body
sodium-fluid volume state. In fact, the addition of thiazide-
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typediuretics to calcium antagonists can enhance the antihyper-
tensive effect [11, 12].
Some calcium antagonists may acutely promote renal sodium
excretion [13—17], but no data on body sodium during such
treatment, alone or in combination with diuretics, are available.
Observations on cardiovascular pressor responsiveness in hu-
mans receiving calcium antagonists are scant and partly incon-
sistent [7—10]. Yet another aspect deserving clarification is the
question whether and to what extent calcium antagonists may
block the pressor influence [18, 19] of an increase in serum
calcium. The present study was designed to address these three
problems. The body sodium-blood volume state, pressor re-
sponsiveness to NE, All, or calcium as related to concomitant
plasma NE, All, and calcium concentrations, as well as the
responsiveness of plasma aldosterone to All, were evaluated in
patients with benign essential hypertension under placebo con-
ditions and following 6 to 8 weeks of treatment with the calcium
antagonist nifedipine alone or in combination with the diuretic
chlorthalidone.
Methods
Subjects
Ten patients (6 women and 4 men) with mild essential
hypertension, aged 44 to 69 yrs [mean 56.7 2.5 (± SEM) yrs]
were studied. Arterial hypertension was defined by repeated BP
measurements> 140/90 mm Hg during a 3-month observation
period. Secondary forms of hypertension were excluded by the
usual tests. None of the patients showed clinical or laboratory
evidence of congestive heart failure, cardiac arrhythmia, edema
or renal failure (as defined by a serum creatinine 130
jimole/liter). Six patients were untreated; in the other four, all
antihypertensive drugs and potassium supplements were dis-
continued at least 4 weeks before study. The patients, who had
given their informed consent to the study, were instructed to
ingest a normal diet, but without salty foods or adding salt to
their food [20].
Patients were started on placebo, one capsule t.i.d. for 4
weeks. The placebo capsules were then replaced by the calcium
antagonist niledipine, 10 mg t.i.d. This dose was increased to 20
mg t.i.d. in two patients in whom BP was still 165/100mm Hg
after 2 weeks of treatment. The mean dose from the third week
on was 36 3 (± sEM) mg/day. Dosing of nifedipine t.i.d. has
been found adequate to provide a sustained drug effect, partic-
ularly after 6 weeks of administration [21].
After 6 to 8 weeks nifedipine monotherapy, the diuretic
chlorthalidone, 25 to 50 mg/day [mean dose 34 3 (± SEM)
mg/day], was added to nifedipine during an additional 6- to
8-week period. The study was conducted single-blind. At the
end of each period (placebo phase, nifedipine, nifedipine +
chlorthalidone), the following studies (A, B, and C) were
performed, after overnight fast on three different mornings
within 4 to 6 days.
Study A
Sixty Ci of 24Na were administered and 24-hr urine was
collected for determination of 24Na [22], sodium, potassium,
calcium, phosphate, NE and epinephrine excretion rates. At the
end of this collection period, BP and heart rate were measured
and blood was drawn for counting of 24Na and for determination
of plasma sodium, potassium, calcium, phosphate, creatinine,
renin activity (PRA), aldosterone, NE and epinephrine levels,
and serum protein concentration. These blood samples were
obtained after 1 hr of recumbency between 8 and 9A.M. through
an indwelling intravenous cannula inserted 60 mm previously.
For measurement of plasma and blood volumes [22, 23], 2.5 pCi
of '251-RIHSA were then injected intravenously through an
intravenous cannula on the contralateral arm, and blood for
determination of whole blood and plasma 1251 concentrations
was drawn from the ipsilateral cannula 10 mm later. BP, heart
rate, PRA, aldosterone, NE and epinephrine levels were mea-
sured again after 1 hr of ambulation, according to our standard
procedure [20].
Study B
One to 3 days later, an infusion of NE or All was performed
in the supine position as described previously [24, 25]. A dose
of the drug was taken 1 hr before the infusion.
Following a 60-mm equilibration period with slow intrave-
nous infusion of 5% dextrose (6 mI/hr by constant infusion
pump), basal BP and heart rate were obtained and blood
samples were drawn from the arm contralateral to the infusion
through an indwelling intravenous cannula (inserted 45 to 60
mm previously) for determination of basal PRA, NE and
epinephrine levels. These blood samples were collected be-
tween 8:30 and 9:30 A.M. The dextrose solution was then
replaced by a solution of NE (l-norepinephrine-bitartrate) in
5% dextrose, which was infused continuously at step-wise
increasing dose rates of 20, 40 and 100 ng/kg/min; in four of the
patients a further dose of 200 ng/kg/min had to be given to
achieve the target increase in mean BP (20 mm Hg). Each dose
was infused during 20 mm. BP and heart rate were measured
every mm during the last 10 mm of each infusion step; at the end
of each infusion period, blood was collected from the arm
contralateral to the infusion for determination of plasma NE.
The NE infusion was replaced by 5% dextrose, which was
infused during 45 to 60 mm at constant rate. After this second
equilibration period, basal blood pressure, heart rate, PRA, Al!
and aldosterone levels were determined; the dextrose infusion
was then replaced by a solution of All (Hypertensin, Ciba,
Basel, Switzerland) in 5% dextrose, which was infused contin-
uously at increasing dose rates of 2, 4 and 10 ng/kg/min. In three
of the patients, a further dose of 20 ng/kg/min had to be given to
increase the diastolic BP by at least 20 mm Hg. Each dose was
infused during 20 mi BP and heart rate were recorded as
described previously. At the end of each All infusion step, blood was
drawn for determination of plasma All and aldosterone.
Study C
One to three days later, the response of BP to an acute mild
hypercalcemia was studied. Following an equilibration period
of 60 mm with intravenous infusion of 5% dextrose (6 mI/hr by
constant infusion pump) in the supine position, basal BP and
heart rate were obtained and blood drawn for determination of
plasma calcium, PRA, NE and epinephrine concentrations. The
dextrose solution was then replaced by a solution of calcium-
gluconate, which was infused at a constant rate (0.034 mg
calcium/kg/mm) during 180 mm [7]. BP and heart rate were
recorded every hr, and blood was collected from the arm
contralateral to the infusion for determination of plasma cal-
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cium and, at 120 and 180 mm, for determination of PRA, NE
and epinephrine.
Analytical procedures
BP was measured using standard cuff and sphygmomanome-
ter. Each pressure was a mean of three readings. Phase 5 was
taken as diastolic BP; mean BP was calculated as the sum of the
diastolic (disappearance of sounds) and one-third of the pulse
pressure. During infusion studies, BP was measured with the
automatic recorder Physiometrics SR II (Asulab, Neuchátel,
Switzerland). BP values recorded before and during infusion
were the mean of 10 measurements. Sodium and potassium
were determined by flame photometer, calcium and creatinine
by autoanalyzer, proteins by Biuret and phosphate by Mala-
chite green method [26]. Plasma and blood volume, or ex-
changeable sodium were measured by standard isotope dilution
technique using 1251 human serum albumin and 24Na, respec-
tively [22, 23]. PRA, aldosterone, and All were measured by
radioimmunoassay [27—29], NE and epinephrine in plasma and
urine by a radioenzymatic method [30], as reported previously
from this laboratory [20, 24]. Cardiovascular responsiveness to
NE, All or calcium infusions was analyzed by blood level-BP
response curves [7, 251.
Pressor doses of infused NE or ALt required to increase the
mean (NE-infusion) or diastolic (All-infusion) BP by 20 mm Hg
were calculated from the dose-BP response curves [7, 25]. Total
plasma clearances of infused NE or All were calculated by the
ratio between the infused dose rate and the concomitant varia-
tions in plasma concentration [31, 32]. Since natural logarithmic
transformation rather than absolute values followed a Gaussian
distribution in this and many previous studies [20, 24, 25, 31],
the natural logarithmic transformation of PRA, aldosterone,
NE, epinephrine and pressor doses was used; statistical meth-
ods included paired and unpaired, two-tailed t test, and analysis
of covariance [33].
Results
Study A
Compared to placebo conditions, nifedipine monotherapy
after 6 to 8 weeks was associated with a significant (P < 0.01)
decrease in supine BP and increases in mean body wt (P < 0.05)
and total exchangeable sodium (P < 0.01) (Table 1). No
consistent changes occurred in heart rate, hematocrit, plasma
and blood volumes, plasma and urinary electrolytes, PRA,
plasma aldosterone, plasma and urinary NE and epinephrine
levels.
Combination treatment with nifedipine and chlorthalidone
caused a further slight decrease in supine BP; upright BP also
was significantly reduced as compared to placebo (Table 1).
Exchangeable sodium was restored to the values observed
under placebo conditions, while body wt, plasma, and blood
volume were significantly lowered (P < 0.05 vs. placebo) and
PRA was increased (P < 0.05). The other parameters were not
consistently altered (Table I).
Study B
Compared to placebo conditions, basal (pre-infusion) BP was
lowered significantly (P < 0.05) after nifedipine monotherapy
and decreased further on nifedipine-chlorthalidone combination
treatment (Table 2). Basal (pre-infusion) plasma NE, All, and
aldosterone levels were not consistently modified by nifedipine
monotherapy, but were increased slightly (P < 0.05) on
nifedipine-chlorthalidone combination therapy (Table 2); basal
epinephrine values were stable during the three periods (2.1
0.4, 2,3 0.5, and 2.1 0.7 ng/dl).
Infusion rates of NE or Al! correlated with concomitant
increases in circulating NE or All, respectively (Fig. 1). These
relationships were similar under the three study conditions.
Therefore, the plasma clearances of NE and All during their
infusions also were unaltered (Table 2).
Pressor responsiveness to NE, evaluated by pressor doses,
the slope of infusion rate-BP response curves (Table 2), as well
as plasma NE concentration-BP response curves (Fig. 2), was
not consistently modified on nifedipine monotherapy or combi-
nation treatment. Moreover, the fall in heart rate in response to
the pressor effect of NE infusion was also similar (Fig. 3).
Pressor responsiveness to Al!, evaluated by the same ap-
proach, also was unchanged (Table 2, Fig. 4).
Percentage increases in plasma aldosterone in response to
stepwise increases in circulating All were significantly (P <
0.01) blunted during nifedipine monotherapy or nifedipine-chlor-
thalidone combination treatment as compared to placebo (Fig.
5).
Study C
Calcium was infused during placebo and nifedipine monother-
apy. Basal (pre-infusion) plasma calcium, PRA, NE, and epi-
nephrine levels were similar during the two study conditions
(Table 3). Calcium infusion significantly increased serum cal-
cium (by about 0.3 mmole/Iiter, P < 0.001) and systolic BP (P <
0.01) (Fig. 6). The systolic pressor response to calcium was not
decreased by nifedipine (+ 15 4% vs. + 10 3% on placebo),
although pre-infusion BP was lower during nifedipine treatment.
Side effects
During nifedipine monotherapy, ankle or pretibial edema was
noted in two patients, while palpitations, flush, or tendency for
constipation were each reported by one subject. Leg edema
disappeared during combination treatment, while the three
other symptoms already tended to diminish during monother-
apy phase.
Discussion
Monotherapy with nifedipine in our patients with mild essen-
tial hypertension reduced mean BP by 10% (P < 0.01), but
mean body wt and exchangeable body sodium were signifi-
cantly increased (P < 0.05 and P < 0.01, respectively) after 6 to
8 weeks of such treatment. The addition of the diuretic
chlorthalidone induced a further decrease in blood pressure,
removed the retained body sodium, and slightly but signifi-
cantly lowered blood volume. This interaction with the sodium-
fluid volume state may explain the enhanced antihypertensive
efficacy when calcium antagonists are combined with diuretics
[1, Il, 12].
A previous report described fluid volume retention during
short- to long-term monotherapy with nifedipine [34]. The
tendency for mild and sometimes transient leg edema on
therapy with nifedipine or other calcium antagonists [35] is well
known. On the other hand, renal sodium excretion is increased
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Table 1. Clinical and biochemical features of patients with mild essential hypertension on placebo, after nifedipine alone, and after
nifedipine-diuretic combination treatment
Placebo Nifedipine
Nifedipine +
Chlorthalidone
Blood pressure, mm Hg
supine 151/97 5/2 132a/88b 6/2 124b/83ce 7/3
upright 142/97 5/2 136/96 5/3 l25/93 6/3
Pulse rate, beats/mm
supine 69 3 67 2 64
upright 77 2 79 4 82 3
Body weight, kg 72.7 3.9 73.9 4.Oa 72.1 3.9
Hematocrit, % 41.7 0.6 40.9 3.2 41.9 3.2
Exchangeable sodium, mmoles 2642 237 3360 266b 2638 248
%g 98 6 123 7b 97 7
Blood volume, ml 4210 303 4279 253 3969 333
%g 99 3 101 3 96 4ad
Plasma volume, ml 2621 193 2751 160 2232 231a1
% g 106 6 110 4 94 7a
Plasma sodium, mmoles/liter 141 0.7 142 0.8 139 1.7
potassium, mmoles/liter 4.4 0.1 4.5 0.2 4.5 0.4
calcium, mmoles/lizer 2.3 0.1 2.3 0.1 2.3 0.1
phosphate, mmoles/liter 0.8 0.1 0.8 0.1 0.7 0.1
proteins, gfliter 64 1.1 63 1.0 64 1.5
creatinine, ismo!es/liier 85 6.6 79 6.7 87 5.9
renin activity, ng/ml/hr
supine 1.12 0.9 1.57 0.26 2.60 0.57
upright 1.72 0.49 2.27 0.44 5.63 I.l8
aldosterone, ng/dl
supine 7.27 0.91 6.98 0.79 11.91 2.93
upright 20.34 6.43 28.53 5.33 33.50 7.99
norepinephrine, ng/dl
supine 25.63 7.46 29.83 7.02 25.82 5.21
upright 62.18 13.13 61.77 20.03 56.85 6.71
epinephrine, ng/dI
supine 2.91 0.49 4.02 2.03 2.40 0.55
upright 8.34 2.37 6.38 2.46 3.55 0.63
Urinary sodium, mmoles/24 hr 154 22 158 22 166 20
potassium, mmoles/24 hr 67 10 66 7 61 7
calcium, mmoles/24 hr 4.27 0.50 6.53 0.90 4.29 0,80d
phosphate, mmoles/24 hr 25.8 3.8 27.3 3.7 21.4 3.1
norepinephrine, rsg/g creatinine 18.97 4.70 34.27 9.41 28.85 7.43
epinephrine, /.Lg/g creatinine 6.64 2.97 8.82 2.03 6.43 2.31
Values are mean SEM.
a P < 0.05 compared with placebo.
b P < 0.01 compared with placebo.
P < 0,001 compared with placebo.
d P < 0.05 compared with nifedipine.
P < 0.01 compared with nifedipine.
P < 0.001 compared with nifedipine.
g % of mean value relative to body surface area in 99 normal subjects [23].
acutely by these agents [13—171, but this action may dissipate
within the first week [36]. When body wt was reported during
short-term treatment conditions, it was, on the average, often
unchanged or even slightly decreased on nifedipine or
verapamil monotherapy [1, 3, 21, 37—401. Plasma and/or blood
volumes also were not significantly altered in this or previous
studies [1, 3, 15, 38, 39]. No data on extracellular or total body
water during calcium antagonists treatment are available. How-
ever, the sodium-blood volume constellation found in the
present study may suggest that nifedipine led to an accumula-
tion of sodium in particular outside of the extracellular space. In
fact, the 1.2 kg increase in body wt during nifedipine
monotherapy would suggest an increase in extracellular fluid
volume of about 5%, which was matched by a 5% increase in
plasma volume. However, exchangeable sodium was increased
on average by 27%. The relative contribution of this excess in
sodium to extracellular compartments that are relevant (vascu-
lar tissues) or irrelevant (bone, certain organs) is unknown.
Moreover, the persistent antihypertensive efficacy of a calcium
antagonists monotherapy in studies lasting up to 6 months [1]
supports the contention that relevant body sodium-fluid volume
retention, leading to progressive BP resistance, is not a preva-
lent characteristic of calcium antagonists, as it is of the direct
arteriolar vasodilators such as the hydralazines or minoxidil.
Sodium handling by the kidneys in the established phase of
nifedipine-monotherapy remains to be clarified. Activation of
the sympathetic and renin-angiotensin systems could possibly
constitute a sodium-retaining tendency in the early phase of
treatment [1, 5, 6]. However, thereafter plasma renin and
catecholamines tend to return to pre-treatment values, and their
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Table 2. Norepinephnne and angiotensin II infusion in patients with essential hypertension on placebo and after nifedipine monotherapy and
nifedipine-diuretic combination treatment
Placebo Nifedipine
Nifedipine +
Chiorthalidone
Basal BP, mm Hg
Basal heart rate, beats/mm
141/92 3/3
69 2
127a/87 3/3
67 2
13bd/50ce 6/2
65 3
NE Infusion
Basal plasma NE, ng/dl
NEpressordose,ng/kg/min
Mean slope
Plasma NE clearance, liter/mm
15.6 4.2
113 19
10.7 0.8
5.8 1.1
25.8 4.7
135
9.3 1.6
5.5 1.4
30.0 4,6b
110 18
12.6 1.5
5.9 0.8
All Infusion
Basal plasma A!!, pg/mi
Basal plasma aldosterone, ng/dl
All pressor dose, ng/kg/min
Mean slope
Plasma All clearance, liter/mm
8.9 1.0
4.7 0.8
6.2 2.0
10.4 1.1
5.0 0.8
9.4 1.5
8.9 2.0
7.9 2.5
7.7 2.4
4.9 1.1
22.3 4.5
13.8 2.7
9.7 3.9
9.4 3.1
4.2 0.4
Values are mean SEM.
Significance levels as in Table I.
Fig. 1. Correlations between plasma norepinephrine and norepinephrine infusion rates (left graph) and between plasma angiotensin II and
angiotensin 11 infusion rates (right graph) in patients with essential hypertension on placebo, nifedipine monotherapy and nifedipine-diurezic
treatment, Abbreviations are: NIF, nifedipine; CHLOR, chlorthalidone. Symbols are (left panel): 0, placebo (r = 0.45, P < 0.05);•, NIF (r
0.54, P < 0.01); A, NIF + CHLOR (r = 0.83, P = <0.001). Right panel: Symbols are the same. Correlation coefficients and probability are: r
= 0.84, P < 0.001; r = 0.58, P < 0.001; r = 0.81, P = <0.001, respectively.
unchanged levels after 6 to 8 weeks of nifedipine monotherapy
in the present study are consistent with this interpretation.
Plasma aldosterone levels were not increased on nifedipine
therapy in this and previous investigations [1, 5, 41]. Vascular
permeability may be increased [35]; this may promote a certain
extravascular shift of fluid with sodium, and the resulting
tendency for blood volume contraction could be compensated
by a finite degree of renal sodium retention. The latter may also
be favored by the setting of BP on a lower level.
Since aldosterone production in vitro requires calcium [42],
the possibility of an inhibitory influence of calcium antagonists
must be considered. The responsiveness of circulating aldoster-
one to step-wise increasing blood levels of All was distinctly
reduced (P < 0.01) following 6 to 8 weeks nifedipine monother-
apy or nifedipine-diuretic combination treatment in our patients
with mild essential hypertension, but not following 2 weeks of
nifedipine monotherapy in a previously studied group of normal
or borderline hypertensive subjects [7]. Others noted an imme-
diate blunting of aldosterone response during All infusion by
nifedipine in normal subjects [43] or an acute marked lowering
of plasma aldosterone by nifedipine in primary hyperaldoster-
onism [44]. Since nifedipine-induced vasodilation could possi-
bly elevate liver blood flow, a partial contribution of an in-
creased hepatic clearance to lower plasma aldosterone levels
cannot be excluded [45]. Using a calcium antagonist with less
vasodilating potential, namely verapamil, aldosterone stimula-
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Fig. 2. Relationship between increases in plasma norepinephrine and
changes in mean blood pressure during norepinephrine infusion in
patients with mild essential hypertension. Horizontal and vertical bars
represent SEM. Symbols are the same as Fig. I.
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Plasma angiotensin II, pg/mi
Fig. 4. Relationship between increases in plasma angiotensin II con-
centrations and changes in diastolic blood pressure during angiotensin
II infusion in patients with mild essential hypertension. Horizontal and
vertical bars represent SEM. Symbols are the same as Fig, 1.
tion by All in normal subjects was significantly depressed at 5
days, but not acutely after drug application [101. The interaction
between calcium antagonists and adrenal cortical function may
depend on several factors, such as type and dosage of the agent,
the subject's biological condition, and perhaps also the duration
of pharmacological calcium antagonism. Moreover, at least
nifedipine seems to interfere with aldosterone release by an
All-independent mechanism, as suggested by the potent aldos-
terone inhibition in a high aldosterone-low renin state [44].
Cardiovascular pressor responsiveness to NE and All was
not consistently altered following 6 to 8 weeks of nifedipine
monotherapy in our hypertensive patients. The duration of
pharmacological calcium antagonism could again play a role.
After 4 weeks of monotherapy, pressor reactivity to NE was
still lowered by nifedipine, but not by verapamil [9]. After 2
weeks of nifedipine monotherapy, NE responsiveness was
decreased and All responsiveness unaltered in normal or
borderline hypertensive subjects [7]. Finally, reductions in the
pressor reactivity to both NE and All were noted following a
single dose of nifedipine in normal subjects [8].
The finding, and perhaps the restoration, or largely unaltered
cardiovascular pressor responses in the established phase of
nifedipine monotherapy may not be surprising, since these
reactions seem to be at least partly independent of extracellular
calcium. Apart from transmembranous calcium influx through
the slow channels, NE-induced contraction depends also on
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Fig. 3. Relationship between norepinephrine-induced increases in mean
blood pressure and concomitant decreases in heart rate in patients with
mild essential hypertension. Horizontal and vertical bars represent
SEM. Symbols are the same as Fig. I.
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Fig. 5. Relationship between increases in plasma angiotensin II and
changes in plasma aldosterone levels during angiotensin II infusion in
patients with mild essential hypertension. Horizontal and vertical bars
represent SEM. Symbols are the same as Fig. 1.
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Table 3. Basal data before calcium infusion in patients with essential
hypertension on placebo and after nifedipine
Placebo Nifedipine
Basal BP, mm Hg 139/92 4/3 127a/85 3/3
Basal heart rate, beats/mm 68 3 67 2
Plasma calcium, mmoles/liter 2.2 0.1 2.2 0.1
renin activity, ng/ml/hr 1.2 0.3 1.2 0.2
norepinephrine, ng/dl 25.3 3.1 35.0 9.1
epinephrine, ng/dl 1.8 0.4 2.8 0.7
Values are mean SEM.
Significance levels as in Table I and 2.
0 1 2 3
Duration of calcium infusion, hr
Fig. 6. Serum calcium and blood pressure before and during intrave-
nous calcium infusion on placebo and after nifedipine monotherapy in
patients wish mild essential hypertension. Vertical bars represent
SEM. Significance levels * P < 0.05; ** P <0.01; " P < 0.001 vs. basal
conditions. § P < 0.05 vs. placebo. Symbols are the same as Fig. I.
essential hypertension without altering cardiovascular respon-
siveness to major pressor hormones.
The increase in systolic and, to a lesser extent, diastolic BP
accompanying mild hypercalcemia [18, 19] was not inhibited by
nifedipine in our patients. This suggests that pressor responses
during acute hypercalcemia are not mediated by an enhanced
influx of calcium through the slow transmembranous channels.
The preferential influence on systolic BP may possibly suggest
a decreased compliance and diameter of large arteries as a
pathogenetic component. One investigator has even proposed
that a factor other than hypercalcemia per se may be responsi-
ble for the rise in BP in this setting [49]. Whatever the exact
mechanisms of hypercalcemia-associated acute hypertension,
our observations suggest that a calcium infusion remains a
potential BP-elevating maneuver even in the presence of phar-
macological calcium antagonism. Intravenous calcium has al-
ready been found to improve unwanted cardiodepression in-
duced by certain calcium antagonists [50].
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